Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mariel Therapeutics, a clinical stage therapeutic company focusing on Bone Morphogenetic Protein-7 and its application in Osteoarthritis (OA) and Chronic Kidney Disease (CKD), has announced that the US Patent and Trademark Office (USPTO) has issued two new patents related to BMP-7 in OA and CKD.
Subscribe to our email newsletter
The newly issued patents expand the already large intellectual property estate surrounding BMP-7, which include over 450 issues and pending patents, and extends important intellectual property in OA and CKD.
"These newly issued patents contain broad claims which provide important long-term exclusivity for BMP-7 and its use in OA and CKD," said Joseph Hernandez, Chairman of Mariel Therapeutics. "Collectively, they further expand Mariel’s intellectual property estate surrounding BMP-7, enhancing its commercial potential."
Mariel Therapeutics (Mariel) is a clinical stage biopharmaceutical company focused on the clinical application of Bone Morphogenetic Protein-7 (BMP-7) in osteoarthritis (OA), chronic kidney disease (CKD), and Alport’s Syndrome.
Mariel acquired the rights to over 450 issued and pending patents as well as BMP-7-related clinical and research data, and the associated biologic materials from Stryker Corporation.
Human recombinant BMP-7 has previously been used in reconstructive bone applications in over 40,000 patients. Previous Phase I and Phase IIa trials have been completed in osteoarthritis.
Mariel intends to advance clinical trial in osteoarthritis (OA) and for chronic kidney disease (CKD) and Alport’s disease, a genetic kidney fibrosis disease.